Bausch + Lomb Corporation (BLCO): Price and Financial Metrics

Bausch + Lomb Corporation (BLCO): $17.60

0.28 (+1.62%)

POWR Rating

Component Grades








BLCO Price/Volume Stats

Current price $17.60 52-week high $21.95
Prev. close $17.32 52-week low $13.62
Day low $17.05 Volume 682,400
Day high $17.70 Avg. volume 530,378
50-day MA $15.16 Dividend yield N/A
200-day MA $17.23 Market Cap 6.18B

BLCO Stock Price Chart Interactive Chart >


  • Growth is the dimension where BLCO ranks best; there it ranks ahead of 96.08% of US stocks.
  • BLCO's strongest trending metric is Quality; it's been moving down over the last 167 days.
  • BLCO's current lowest rank is in the Momentum metric (where it is better than 18.05% of US stocks).

BLCO Stock Summary

  • With a one year PEG ratio of 0.77, BAUSCH & LOMB CORP is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 7.01% of US stocks.
  • BLCO's went public 1.67 years ago, making it older than just 1.29% of listed US stocks we're tracking.
  • The price/operating cash flow metric for BAUSCH & LOMB CORP is higher than 92.32% of stocks in our set with a positive cash flow.
  • If you're looking for stocks that are quantitatively similar to BAUSCH & LOMB CORP, a group of peers worth examining would be MYGN, CPIX, FNA, ASYS, and KODK.
  • To dig deeper into the stock's financial statements, go to BLCO's page on browse-edgar?action=getcompany&CIK=0001860742.

BLCO Valuation Summary

  • BLCO's price/sales ratio is 1.5; this is 64.29% lower than that of the median Healthcare stock.
  • BLCO's price/sales ratio has moved down 0.4 over the prior 20 months.

Below are key valuation metrics over time for BLCO.

Stock Date P/S P/B P/E EV/EBIT
BLCO 2023-12-29 1.5 0.9 -28.9 91.7
BLCO 2023-12-28 1.5 0.9 -28.5 90.9
BLCO 2023-12-27 1.5 0.8 -27.9 89.8
BLCO 2023-12-26 1.4 0.8 -27.0 88.1
BLCO 2023-12-22 1.4 0.8 -26.8 87.7
BLCO 2023-12-21 1.4 0.8 -26.7 87.7

Bausch + Lomb Corporation (BLCO) Company Bio

Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada.

BLCO Latest News Stream

Event/Time News Detail
Loading, please wait...

BLCO Latest Social Stream

Loading social stream, please wait...

View Full BLCO Social Stream

Latest BLCO News From Around the Web

Below are the latest news stories about BAUSCH & LOMB CORP that investors may wish to consider to help them evaluate BLCO as an investment opportunity.

Bausch + Lomb CEO Brent Saunders Pays $35.35 Million for Cher’s Former Miami Beach Home

Bausch + Lomb CEO Brent Saunders has purchased Cher’s former waterfront home in Miami Beach, Fla., for $35.35 million. The La Gorce Island home, which Cher owned in the 1990s, hit the market three months ago for $42.5 million. Saunders, who is also the former CEO of the Botox maker Allergan, said he bought the property with his wife, Daniela Botero Correa.

Yahoo | November 28, 2023

Is Bausch + Lomb Corporation (NYSE:BLCO) Trading At A 39% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Bausch + Lomb fair value estimate is US$25.50 Current share...

Yahoo | November 21, 2023

Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

VAUGHAN, Ontario, November 15, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE and Biotrue Eye Care Recycling programs have collected a total of 76,645,000 million units, or 464,100 pounds, of used contact lenses, eye care and lens care materials in the United States, which is equivalent to the weight of 140 hippos1.

Yahoo | November 15, 2023

Bausch & Lomb Corp (BLCO) Reports Q3 2023 Earnings and Raises Full-Year Guidance

Revenue Grows 7% to $1.007 Billion, Despite Net Loss of $84 Million

Yahoo | November 1, 2023

Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance

VAUGHAN, Ontario, November 01, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2023 financial results.

Yahoo | November 1, 2023

Read More 'BLCO' Stories Here

BLCO Price Returns

1-mo 22.48%
3-mo 15.71%
6-mo -4.14%
1-year -3.98%
3-year N/A
5-year N/A
YTD 3.17%
2023 9.99%
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!